Publication | Closed Access

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

Cetuximab EfficacyMedicinePathologyColorectal CancerMetastatic Colorectal CancerCancer GenomicsClinical UsefulnessCancer GeneticsCancer TreatmentOncologyRadiation Oncology